Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 9

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 9
---
 explore the mechanism of action
and specific neural targets of MEAI to evaluate its efficacy as a potential therapeutic agent in the treatment of addiction and related
behaviors. The results of pre-clinical research studies suggested that MEAI may be effective in the treatment of substance addiction
and specifically cocaine without interrupting the natural reward process. According to the United Nations Office on Drugs and Crime’s
“2022 World Drug Report”, of the estimated 284 million people who had used drugs in the past year, approximately 13.6%, 38.6
million, are estimated to have suffered from drug use disorders. While some addictions, such as drugs and alcohol, are more concerning
than others, addiction and compulsive behavior is not limited to these substances. Compulsive consumption of food, shopping, gambling,
sex, television, and technology, many of which increased in prevalence during the recent pandemic, can all be destructive when their
use cannot be managed and all can potentially be treated by MEAI.

Corporate Information

We were incorporated under the name Cyntar Ventures
Inc. on July 18, 2017, pursuant to the provisions of the Business Corporations Act(British Columbia). On March 24,
2021, we changed our name to Clearmind Medicine Inc.

Our principal executive offices are located at
101 – 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016. Our website address is https://www.clearmindmedicine.com/.
The information contained on our website and available through our website is not incorporated by reference into and should not be considered
a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only.

January 2024 Offering

On January 11, 2024,
we sold to several institutional investor an aggregate of 1,468,000 common shares in a registered direct offering at a purchase price
of $1.60 per share, and pre-funded warrants to purchase up to 32,000 common shares at a purchase price of $1.5999, resulting in gross
proceeds of approximately $2.4 million. In addition, we issued to the investors unregistered common warrants, or the January 2024
PIPE Warrants, to purchase up to an aggregate of 1,500,000 common shares in the concurrent January 2024 Private Placement. The January
2024 PIPE Warrants are exerc